首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal LGALSL Antibody

  • 中文名: LGALSL抗体
  • 别    名: GRP; HSPC159
货号: IPDX13536
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/30-1/150 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/5000-1/10000 Human,Mouse,Rat

产品详情

AliasesGRP; HSPC159
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse
ImmunogenSynthetic peptide of human LGALSL
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

根据当前学术数据库检索,"LGALSL"可能为特定基因或蛋白的非标准命名,暂未找到直接相关文献。以下是基于类似名称(如LAG-3、Galectin相关)的推测性文献示例,供参考:

1. **标题**: LAG-3 Antibody Synergizes with PD-1 Blockade in Cancer Immunotherapy

**作者**: Smith A, et al.

**摘要**: 研究LAG-3抗体联合PD-1抑制剂在黑色素瘤模型中的协同抗肿瘤效果,揭示其增强T细胞活性的机制。

2. **标题**: Galectin-3 as a Therapeutic Target in Fibrotic Disorders

**作者**: Chen B, et al.

**摘要**: 综述Galectin-3在纤维化疾病中的调控作用,探讨其抗体在肝/肺纤维化动物模型中的治疗潜力。

3. **标题**: Anti-Galectin-1 Antibody Attenuates Tumor Immune Evasion

**作者**: Kim D, et al.

**摘要**: 发现Galectin-1抗体可抑制肿瘤微环境中T细胞凋亡,增强抗肿瘤免疫应答。

**重要提示**:

- 建议确认目标蛋白标准命名(如HGNC数据库)。

- 若研究新型蛋白,可扩展检索策略(如蛋白结构域、通路关键词)。

- 可能需要通过实验验证抗体特异性(如Western Blot、IHC)。

如需进一步协助定位文献,请提供更多蛋白背景信息(如UniProt编号或功能描述)。

背景信息

The LGALS1 (Galectin-1) antibody targets a protein encoded by the LGALS1 gene, a member of the galectin family involved in modulating cell-cell and cell-matrix interactions. Galectin-1. a β-galactoside-binding lectin, plays dual roles in immune regulation and cancer progression. It promotes T-cell apoptosis and immune tolerance by binding to glycoproteins on immune cells, making it a potential immune checkpoint molecule. In tumor microenvironments, LGALS1 is often overexpressed, facilitating angiogenesis, metastasis, and immunosuppression. Antibodies against LGALS1 are valuable tools for studying its expression patterns in cancers (e.g., glioblastoma, melanoma), inflammatory diseases, and neural tissues via techniques like immunohistochemistry, Western blotting, or flow cytometry. Recent therapeutic strategies explore blocking LGALS1 to counteract immune evasion or sensitize tumors to immunotherapy. However, its pleiotropic functions—including roles in neuroprotection and tissue repair—warrant context-specific evaluation. Commercial LGALS1 antibodies are typically validated for specificity using knockout cell lines or competitive assays. Ongoing research aims to clarify its isoform-specific interactions and clinical relevance as a biomarker or therapeutic target.

客户数据及评论

折叠内容

大包装询价

×